Identification of Multimorbid Patients With a Higher Probability of Readmission and Mortality

Multimorbidity Clinical Trial

Official title:

Identification of Multimorbid Patients With a Higher Probability of Readmission and Mortality: Role of Patient-related Variables

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05574790
• Other study ID #: PI18/01438
• Status: Completed
• Start date: February 7, 2022
• Est. completion date: August 30, 2023

Study information

• Verified date: September 2023
• Source: Hospital Galdakao-Usansolo
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A prospective qualitative quantitative study was designed to create predictive models of readmission in multimorbid patients.

Description:

Social determinants have been shown to be related to the probability of readmission and death in multimorbid patients. These are increasingly older, which makes them more likely to be readmitted when their preferences are usually to be at home. Objective: To create and validate prediction models for readmission and mortality during home transitional period (1 month) and up to a year, in multimorbid patients, including variables related to the patient and their social environment. Design: Quali-quantitative. 4 hospitals from 3 regions (Andalucia, Catalonia and the Basque Country) will participate . Patients presenting at least 2 of the Ollero's categories will be included. Variables will be identified by means of nominal groups of professionals and focal groups with patients and caregivers. These variables will be included in the final models join to clinical variables, PROMS (health related quality of life, burden of the caregiver , social support). Logistic/ Cox regression models will be developed and validated internally to identify the risk of readmission and death which will be validated in an external cohort. Expected results: We hope to provide the health system with stratification tools for polypathological patients that help in identifying those patients with the greatest need for individualized interventions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: August 30, 2023
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients over 18 years of age

• Patients discharged from the Internal Medicine departments of the participating centers due to acute pathology, de novo or decompensation of a chronic pathology who also present at least 2 of the cathegories of Ollero et al.

Exclusion Criteria:

• Patients admitted for end-of-life treatment, scheduled admissions, exacerbation of rheumatic pathology or systemic disease, study of anaemia in patients with no-known comorbidity, search for neoplasia and acute processes without associated comorbidity. -

• Failure to sign the informed consent form.

Related Conditions & MeSH terms

• Multimorbidity

Intervention

Other:
• annual follow up
Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality

Locations

Country	Name	City	State
Spain	Hospital del Mar	Barcelona
Spain	Hospital Galdakao Usansolo	Galdakao	Bizkaia
Spain	Hospital Costa del Sol	Marbella	Málaga
Spain	Hospital Universitario Virgen del Rocío	Sevilla

Sponsors (6)

Lead Sponsor	Collaborator
Hospital Galdakao-Usansolo	Asociacion Instituto de Investigacion en Servicios de Salud Kronikgune, Hospital Costa del Sol, Hospital del Mar, Hospitales Universitarios Virgen del Rocío, Instituto de Salud Carlos III

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Readmission	number of readmissions in the early period (transition to discharge, 1 month	1 month
Primary	Readmission	number of readmissions in the annual period	1 year